Arcadia Biosciences, Inc.
RKDANasdaq
$0.67
↓ -2.6%Jul 17 close · end-of-day
Price
1Y↓ -85.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.4M
Enterprise Value
-$2.3M
P/E
—
P/S
0.3
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$4.8M
Net Income (TTM)
-$9.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-80.0%
Net Margin
-195.9%
ROE
-323.1%
ROIC
—
Debt / Equity
—
Net Cash
$3.7M
Return 1Y
-85.2%
Company profile
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products. It engages in developing crop improvements primarily in wheat to enhance farm economics. The company was incorporated in 2002 and is headquartered in Davis, California.
- CEO
- Stanley E. Jacot
- Sector
- Agriculture, Forestry, And Fishing
- Industry
- Agriculture
- Employees
- 60
- Headquarters
- California
- Website
- arcadiabio.com
Earnings
RKDA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.1M↓ -8.3%
Diluted EPS-$2.11↓ -211.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.0M | $6.8M | $7.4M | $4.5M | $5.0M | $4.9M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.8M | -$35.5M | -$14.0M | -$6.1M | -$3.6M | -$2.5M |
| Net income | -$4.7M | -$14.7M | -$15.4M | -$14.0M | -$7.0M | -$2.3M |
| Diluted EPS | — | -$27.56 | -$25.65 | -$11.29 | -$5.17 | -$1.71 |
| Operating cash flow | -$30.2M | -$25.9M | -$14.0M | -$15.3M | -$9.6M | -$4.7M |
| Free cash flow | -$32.6M | -$26.9M | -$14.0M | -$15.3M | -$9.6M | -$4.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -159.0% | -524.0% | -188.8% | -137.0% | -72.3% | -51.5% |
| Net margin | -57.9% | -216.2% | -207.3% | -313.9% | -139.5% | -48.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.5M | $1.2M | $1.2M | $1.5M | $1.3M | $901,000.00 | $1.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $2.0M | -$1.8M | -$2.3M | $530,000.00 | -$501,000.00 | -$1.2M | -$1.4M | -$779,000.00 |
| Net income | $1.1M | -$1.6M | -$4.1M | $2.6M | -$4.5M | $856,000.00 | -$1.3M | -$4.4M |
| Diluted EPS | $0.78 | -$1.18 | -$2.99 | $1.90 | -$3.26 | $0.62 | -$0.97 | -$2.11 |
| Operating cash flow | -$2.5M | -$1.8M | -$2.2M | -$1.6M | -$2.0M | -$257,000.00 | -$822,000.00 | -$1.1M |
| Free cash flow | -$2.5M | -$1.8M | -$2.2M | -$1.6M | -$2.0M | -$257,000.00 | -$822,000.00 | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 151.6% | -114.5% | -187.7% | 44.2% | -34.4% | -88.5% | -152.8% | -70.8% |
| Net margin | 81.2% | -104.9% | -334.5% | 216.6% | -306.4% | 65.7% | -148.3% | -398.6% |
Company news
Mar 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.